Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expanded Access: US FDA Told To Increase Regulatory Clarity, Early Interactions With Sponsors

Executive Summary

Independent assessment finds positive perceptions of expanded access program but calls on agency to do more to correct manufacturer misperceptions about adverse events and clarify when data from expanded access would support labeling extensions.

Advertisement

Related Content

Orphan, Combo, Pediatric Products Would See More Influence In Proposed US FDA Reorg
US FDA's Woodcock: Sponsors Have To Make Right-To-Try Decisions
Posting Preapproval Access Policies Could Help Prevent ‘Blame And Shame’ Under Right To Try
US FDA’s Plan On Right To Try: Big On Congressional Engagement, Short On Policy Details
Expanded Access Programs Eyed For Data-Gathering Purposes
US FDA's Patient Affairs Office Is An Office … In Spirit
Expanded Access Programs Need FDA Policy Changes To Really Expand

Topics

Advertisement
UsernamePublicRestriction

Register

PS124225

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel